Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with new long-term overall survival (OS) ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

AstraZeneca is raising its defenses against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung cancer. | Following an FDA approval last year based on a tumor progression ...

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

Positive high-level results have been presented from the final overall survival (OS) analysis of the FLAURA2 Phase III trial.

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...